Form 4: Iovance Biotherapeutics Director Michael Weiser Reports Acquisition of Deferred Restricted Stock Units

Director Michael Weiser reports acquisition of deferred restricted stock units in Iovance Biotherapeutics.

Summary

• On June 11, 2024, Michael Weiser, a director of Iovance Biotherapeutics, acquired 49,303 deferred restricted stock units (DRSUs).
• These DRSUs represent a contingent right to receive one share of Iovance Biotherapeutics' common stock each.
• The DRSUs were granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
• The DRSUs will vest on the earlier of (i) the first anniversary of the transaction date or (ii) the day prior to the Issuer's next annual shareholder meeting, provided the Reporting Person continues to provide service to the Issuer.
• The issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of deferred stock units, which is a common form of compensation. It doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of DRSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting and issuance of common stock are contingent upon continued service and other conditions as defined in the DRSU agreement.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in the biopharmaceutical industry.

Stakeholder Impact

• The acquisition of DRSUs by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates